Why TG Therapeutics ( TGTX ) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies ( NASDAQ:PLTR )
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. Here's a look at the names most likely to be on individual investors' radars. CIFR stock is soaring. Watch the real-time price action here.
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET ...
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ:TGTX ) , today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.
Arcus Biosciences, Inc. ( RCUS ) Reports Q3 Loss, Beats Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +4.51% and +27.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amgen ( AMGN ) Q3 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics ( TGTX ) Earnings Expected to Grow: What to Know Ahead of Q3 Release
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Climb Bio ( NASDAQ:CLYM )
William Blair initiated coverage for Climb Bio ( NASDAQ:CLYM ) , citing the potential of the company's budoprutug, under development for autoimmune indications, including: Phase 1b/2a immune thrombocytopenia ( ITP ) trial FPI achieved, enrollment ongoing.
Strength Seen in uniQure ( QURE ) : Can Its 247.7% Jump Turn into More Strength?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ: TGTX ) , today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 European Committee for ...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens ...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 - 10, ...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET ...
Why Is TG Therapeutics Stock Surging Wednesday? - TG Therapeutics ( NASDAQ:TGTX )
TG Therapeutics completed a $100 million repurchase, buying 3.5 million shares at $28.55 each. The board approved a new $100 million buyback plan, sending TG Therapeutics stock higher. Post-Labor Day Trading Could Trigger Major Market Moves. Here's How to Trade It TG Therapeutics Inc.
Why Is TG Therapeutics ( TGTX ) Up 4.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
NEW YORK, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ: TGTX ) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024.
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
Company News for Aug 5, 2025
Companies in The News Are: ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - CommScope Holding Co ( NASDAQ:COMM ) , BT Brands ( NASDAQ:BTBD )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.27% to 44,141.11 while the NASDAQ climbed 1.82% to 21,026.44. The S&P 500 also rose, gaining, 1.37% to 6,323.33. Communication services shares jumped by 2.3% on Monday.
Why Is TG Therapeutics Stock Falling Monday? - TG Therapeutics ( NASDAQ:TGTX )
Q2 EPS rose to 17 cents from 4 cents but missed the 19 cents consensus; revenue reached $141.2 million vs. $146.4 million expected. Briumvi Q2 U.S. revenue hit $138.8 million, up 91% YoY, beating guidance of $135 million. The next correction is closer than you think.
TG Therapeutics Q2 Revenue Up 91%
TG Therapeutics ( NASDAQ:TGTX ) , which specializes in treatments for autoimmune diseases, released its second-quarter 2025 earnings on August 4, 2025. The headline news was strong sales growth for BRIUMVI, its infusion therapy for relapsing multiple sclerosis, prompting management to raise its ...
TG Therapeutics ( TGTX ) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals ( ACAD ) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET ...
TG Therapeutics ( TGTX ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights
San Francisco, USA, July 22, 2025 ( GLOBE NEWSWIRE ) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate ( CAGR ) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032.
Cramer Backs This Mining Giant After $1.6B Bet - TG Therapeutics ( NASDAQ:TGTX ) , Rio Tinto ( NYSE:RIO )
Cramer endorses Rio Tinto following $1.6B Hope Downs 2 expansion deal. TG Therapeutics beats Q1 estimates, sees strong BRIUMVI adoption and momentum. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock - TG Therapeutics ( NASDAQ:TGTX )
Yann Echelard, Director at TG Therapeutics TGTX, disclosed an insider sell on June 16, according to a recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Echelard sold 10,000 shares of TG Therapeutics.
Are Options Traders Betting on a Big Move in TG Therapeutics Stock?
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET.
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, June 06, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025.
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, ...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ: TGTX ) , today announced the presentations of data highlighting BRIUMVI® ( ublituximab-xiiy ) in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( CMSC ...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, May 30, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the presentations of data highlighting BRIUMVI® ( ublituximab-xiiy ) in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( CMSC ) annual ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( ...
Should First Trust Small Cap Core AlphaDEX ETF ( FYX ) Be on Your Investing Radar?
Style Box ETF report for ...
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show - TG Therapeutics ( NASDAQ:TGTX )
Q1 EPS of $0.03 beats the estimate of -$0.17; revenue hit $120.86 million, up from $63.47 million YoY. Briumvi U.S. sales hit $119.7 million; TG Therapeutics ups 2025 guidance to $560 million from $525 million. Feel unsure about the market's next move?
Why TG Therapeutics Stock Was Tumbling Today
A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics ( NASDAQ: TGTX ) shareholders on Monday.The company, best known for its multiple sclerosis ( MS ) drug Briumvi, posted its first-quarter results that morning, and ...
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Hyperscale Data ( AMEX:GPUS ) , BioCryst Pharma ( NASDAQ:BCRX )
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday. The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&P 500 also fell, dropping, 0.26% to 5,671.90. Industrials shares rose by 0.2% on Monday.
TG Therapeutics ( TGTX ) Lags Q1 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million ...
Alnylam Pharmaceuticals ( ALNY ) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 98.21% and 1.02%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics ( TGTX ) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
Conference call to be held Monday, May 5, 2025, at 8:30 AM ET Conference call to be held Monday, May 5, 2025, at 8:30 AM ET ...
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, April 30, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.
Is First Trust Small Cap Core AlphaDEX ETF ( FYX ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Price Over Earnings Overview: TG Therapeutics - TG Therapeutics ( NASDAQ:TGTX )
Looking into the current session, TG Therapeutics Inc. TGTX shares are trading at $36.50, after a 0.57% decrease. Over the past month, the stock decreased by 3.89%, but over the past year, it actually spiked by 173.79%.
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
